0001680048false00016800482022-06-212022-06-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 21, 2022

Mustang Bio, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

    

001-38191

    

47-3828760

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

377 Plantation Street

Worcester, Massachusetts 01605

(Address of Principal Executive Offices)

(781) 652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

MBIO

 

NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As described under Item 5.07 of this Current Report on Form 8-K (the “Current Report”), on June 21, 2022, the stockholders of Mustang Bio, Inc. (the “Company” or “Mustang”) voted at the Company’s 2022 annual meeting of stockholders (the “2022 Annual Meeting”) to approve an amendment (the “Plan Amendment”) to the Company’s 2016 Incentive Plan (the “Incentive Plan”) to increase the shares of common stock, par value $0.0001 per share (the “Common Stock”) available for issuance under the Incentive Plan by 3,000,000 shares from 8,000,000 shares to 11,000,000 shares.

The Company’s Board of Directors approved the Plan Amendment on April 7, 2022, subject to stockholder approval at the 2022 Annual Meeting. The Plan Amendment became effective at the time of stockholder approval.

A copy of the Plan Amendment is filed as Exhibit 10.1 to this Current Report and is incorporated by reference in this Item 5.02. The material terms of the Incentive Plan as so amended are described in the Company’s definitive proxy statement on Schedule 14A for the 2022 Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2022.

Item 5.07    Submission of Matters to a Vote of Security Holders.

Mustang held its 2022 Annual Meeting of stockholders on June 21, 2022 by means of an online virtual meeting platform at 1:00 p.m. Eastern Time. At the annual meeting, the following four proposals were approved: (i) the election of six directors to hold office until the 2023 annual meeting; (ii) the ratification of the appointment of KPMG LLC as Mustang’s independent registered public accounting firm for the year ending December 31, 2022; (iii) an amendment to Mustang’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 50,000,000 shares from 150,000,000 to 200,000,000; and (iv) an amendment to Mustang’s 2016 Incentive Plan to increase the shares of common stock available for issuance under the 2016 Incentive Plan by 3,000,000 shares. The four proposals are described in detail in Mustang’s definitive proxy statement dated April 29, 2022 for the annual meeting.

As of the April 25, 2022 record date for the determination of the shareholders entitled to notice of, and to vote at, the 2022 Annual Meeting, 101,633,830 shares of the Company’s Common Stock were outstanding and eligible to vote with an aggregate of 101,633,830 votes; 845,385 shares of the Company’s Class A Common Stock were outstanding and eligible to vote with an aggregate of 845,385 votes; and 250,000 shares of the Company’s Class A Preferred Stock were outstanding and eligible to vote with an aggregate of 113,000,000 votes, as determined in accordance with Section 3.1.3 of the Company’s Amended and Restated Articles of Incorporation. Approximately 88% of all votes were represented at the 2022 Annual Meeting, constituting a quorum.

Proposal 1

The votes with respect to the election of six directors to hold office until the 2023 annual meeting were as follows:

Director

 

For

 

 

Withheld

 

Broker Non-Votes

Michael S. Weiss

 

140,072,084

 

 

12,408,705

 

36,178,045

Lindsay A. Rosenwald, M.D.

 

140,101,138

 

 

12,379,651

 

36,178,045

Neil Herskowitz

 

137,683,727

 

 

14,797,062

 

36,178,045

Manuel Litchman, M.D.

 

143,907,944

 

 

8,572,845

 

36,178,045

Adam Chill

 

140,434,682

 

 

12,046,107

 

36,178,045

Michael Zelefsky, M.D.

 

140,443,567

 

 

12,037,222

 

36,178,045

Proposal 2

The votes with respect to the ratification of KPMG LLP as Mustang’s independent registered accounting firm for the year ending December 31, 2022 were as follows:

Total Votes For

 

 

Total Votes Against

 

 

Abstentions

 

 

 

 

188,060,244

 

 

 

412,782

 

 

 

185,808

 

 

 

 

Proposal 3

The votes with respect to the approval of an amendment to Mustang’s Amended and Restated Certificate of Incorporation were as follows:

Total Votes For

 

 

Total Votes Against

 

 

Abstentions

 

 

Broker Non-Votes

 

 

180,248,356

 

 

 

5,870,066

 

 

 

2,540,412

 

 

 

0

 

Proposal 4

The vote with respect to the approval of an amendment to Mustang’s 2016 Incentive Plan were as follows:

Total Votes For

 

 

Total Votes Against

 

 

Abstentions

 

 

Broker Non-Votes

 

 

150,558,080

 

 

 

1,625,238

 

 

 

297,471

 

 

 

36,178,045

 

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed as part of this report:

Exhibit
Number

 

Description

 

 

 

10.1

 

Third Amendment to Mustang Bio, Inc. 2016 Incentive Plan

 

 

 

104

 

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Mustang Bio, Inc.

 

(Registrant)

Date: June 24, 2022

 

 

By:

/s/ Manuel Litchman, M.D.

 

 

Manuel Litchman, M.D.

 

 

President and Chief Executive Officer